Development of autoimmunity in patients with common variable immune deficiency

September 24, 2013

Common variable immune deficiency (CVID) is a genetic disease associated with enhanced susceptibility to infection, autoimmunity, and decreased antibody production. Mutations in the tumor necrosis factor receptor superfamily member TACI, are associated with CVID and autoimmunity development. Interestingly, autoimmunity develops in CVID patients with only one mutated copy of TACI, and CVID patients with two mutated TACI alleles do not develop autoimmunity.

In this issue of the Journal of Clinical Investigation, Eric Meffre and colleagues at Yale University evaluated B cell activation and tolerance development in healthy individuals and CVID patients with one or two mutated copies of TACI. The authors found that CVID patients with a single altered TACI allele maintained some residual B cell responsiveness that promoted development of autoantibodies, whereas individuals with 2 mutated copies of TACI have complete impairment of B cell responses, which likely prevents autoimmunity.

In the companion commentary, Antonia La Cava of the University of California Los Angeles suggests that targeting residual B cell activity in CVID patients that are heterozygous for TACI mutations may provide clinical relief.

Explore further: How defects in a signaling protein sabotage the immune system in multiple, seemingly contradictory ways

More information: CVID-associated TACI mutations affect autoreactive B cell selection and activation, J Clin Invest. DOI: 10.1172/JCI69854

Related Stories

Body's 'safety procedure' could explain autoimmune disease

September 5, 2013

Monash University researchers have found an important safety mechanism in the immune system that may malfunction in people with autoimmune diseases, such as Multiple Sclerosis, potentially paving the way for innovative treatments.

Recommended for you

How do white blood cells move so fast?

November 22, 2016

If you fall and scrape a knee, it's the job of white blood cells called neutrophils to rush to the site of infection and chase down invading bacteria.

New treatment for allergic response targets mast cells

November 21, 2016

Researchers from North Carolina State University and the National Institutes of Health (NIH) have developed a method that stops allergic reactions by removing a key receptor from mast cells and basophils. Their work has implications ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.